Ragene Rivera, MD, medical oncologist, Texas Oncology-El Paso Cancer Treatment Center, discusses how she decides between hormone therapies in patients with ER+/PR+ tumors.
Ragene Rivera, MD, medical oncologist, Texas Oncology-El Paso Cancer Treatment Center, discusses how she decides between hormone therapies in patients with ER+/PR+ tumors.
This segment is a part of our Case-Based Peer Perspectives.View the case details > >
Roundtable Roundup: Adjuvant Therapy for HR+, HER2- Breast Cancer
June 17th 2025In separate, live virtual events, William J. Gradishar, MD; and Tiffany A. Traina, MD, discussed multiple scenarios for a patient with hormone receptor–positive, HER2-negative breast cancer to potentially receive hormonal plus endocrine therapy.
Read More